Skip to Content

As a result of the current Federal government funding situation, the information on this website may not be up to date or acted upon.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit

Updates regarding government operating status and resumption of normal operations can be found at

Discovering the causes of cancer and the means of prevention

Publications Search - Abstract View

Title: Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium.
Authors: Gaudet MM,  Milne RL,  Cox A,  Camp NJ,  Goode EL,  Humphreys MK,  Dunning AM,  Morrison J,  Giles GG,  Severi G,  Baglietto L,  English DR,  Couch FJ,  Olson JE,  Wang X,  Chang-Claude J,  Flesch-Janys D,  Abbas S,  Salazar R,  Mannermaa A,  Kataja V,  Kosma VM,  Lindblom A,  Margolin S,  Heikkinen T,  Kämpjärvi K,  Aaltonen K,  Nevanlinna H,  Bogdanova N,  Coinac I,  Schürmann P,  Dörk T,  Bartram CR,  Schmutzler RK,  Tchatchou S,  Burwinkel B,  Brauch H,  Torres D,  Hamann U,  Justenhoven C,  Ribas G,  Arias JI,  Benitez J,  Bojesen SE,  Nordestgaard BG,  Flyger HL,  Peto J,  Fletcher O,  Johnson N,  Dos Santos Silva I,  Fasching PA,  Beckmann MW,  Strick R,  Ekici AB,  Broeks A,  Schmidt MK,  van Leeuwen FE,  Van't Veer LJ,  Southey MC,  Hopper JL,  Apicella C,  Haiman CA,  Henderson BE,  Le Marchand L,  Kolonel LN,  Kristensen V,  Grenaker Alnaes G,  Hunter DJ,  Kraft P,  Cox DG,  Hankinson SE,  Seynaeve C,  Vreeswijk MP,  Tollenaar RA,  Devilee P,  Chanock S,  Lissowska J,  Brinton L,  Peplonska B,  Czene K,  Hall P,  Li Y,  Liu J,  Balasubramanian S,  Rafii S,  Reed MW,  Pooley KA,  Conroy D,  Baynes C,  Kang D,  Yoo KY,  Noh DY,  Ahn SH,  Shen CY,  Wang HC,  Yu JC,  Wu PE,  Anton-Culver H,  Ziogoas A,  Egan K,  Newcomb P,  Titus-Ernstoff L,  Trentham Dietz A,  Sigurdson AJ,  Alexander BH,  Bhatti P,  Allen-Brady K,  Cannon-Albright LA,  Wong J,  Australian Ovarian Cancer Study Group,  Chenevix-Trench G,  Spurdle AB,  Beesley J,  Pharoah PD,  Easton DF,  Garcia-Closas M,  Breast Cancer Association Consortium
Journal: Cancer Epidemiol Biomarkers Prev
Date: 2009 May
Branches: MEB, LGS, OD, OEEB, REB
PubMed ID: 19423537
PMC ID: PMC2737177
Abstract: Previous studies have suggested that minor alleles for ERCC4 rs744154, TNF rs361525, CASP10 rs13010627, PGR rs1042838, and BID rs8190315 may influence breast cancer risk, but the evidence is inconclusive due to their small sample size. These polymorphisms were genotyped in more than 30,000 breast cancer cases and 30,000 controls, primarily of European descent, from 30 studies in the Breast Cancer Association Consortium. We calculated odds ratios (OR) and 95% confidence intervals (95% CI) as a measure of association. We found that the minor alleles for these polymorphisms were not related to invasive breast cancer risk overall in women of European descent: ECCR4 per-allele OR (95% CI) = 0.99 (0.97-1.02), minor allele frequency = 27.5%; TNF 1.00 (0.95-1.06), 5.0%; CASP10 1.02 (0.98-1.07), 6.5%; PGR 1.02 (0.99-1.06), 15.3%; and BID 0.98 (0.86-1.12), 1.7%. However, we observed significant between-study heterogeneity for associations with risk for single-nucleotide polymorphisms (SNP) in CASP10, PGR, and BID. Estimates were imprecise for women of Asian and African descent due to small numbers and lower minor allele frequencies (with the exception of BID SNP). The ORs for each copy of the minor allele were not significantly different by estrogen or progesterone receptor status, nor were any significant interactions found between the polymorphisms and age or family history of breast cancer. In conclusion, our data provide persuasive evidence against an overall association between invasive breast cancer risk and ERCC4 rs744154, TNF rs361525, CASP10 rs13010627, PGR rs1042838, and BID rs8190315 genotypes among women of European descent.